101 results
8-K
EX-99.1
IVVD
Invivyd Inc
31 May 24
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
7:12am
of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical … things, the anticipated benefits of the company’s management transition; the company’s plans and expectations related to the commercial launch
8-K
EX-99.2
IVVD
Invivyd Inc
31 May 24
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
7:12am
, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy … regarding the potential benefits, certain anticipated costs, and possible outcomes of utilizing such pathway; the potential of the company’s proprietary
8-K
EX-99.1
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other
8-K
EX-99.1
IVVD
Invivyd Inc
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits … and accelerate product availability; the potential benefits of a new COVID-19 treatment mAb, if authorized or approved, to certain vulnerable
8-K
EX-99.1
brkbtg gyhuf
12 Apr 24
Invivyd Announces CEO Transition
7:36am
8-K
EX-10.1
gsln4juepnacmeh36i
12 Apr 24
Invivyd Announces CEO Transition
7:36am
8-K
EX-99.1
m2sycvwy
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
8-K
EX-99.1
kk0ti2
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am